Cronos Group Inc. (CRON)

16.38
0.78 5.00
NASDAQ : Health Technology
Prev Close 15.60
Open 15.66
Day Low/High 15.40 / 16.55
52 Wk Low/High 5.61 / 25.10
Volume 3.87M
Avg Volume 8.27M
Exchange NASDAQ
Shares Outstanding 334.09M
Market Cap 4.98B
EPS -0.10
P/E Ratio 38.82
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CRON, SFS, TCS, TDW, TPRE Downgrades: AMBC, CARG, IRM, MUR, PEGI, RDFN, RL, TBI Initiations: RDVT Read on to get TheStreet Quant Ratings' detailed report:

Cronos Climbs After Securing Private Label Concentrate Agreement With MediPharm

Cronos Climbs After Securing Private Label Concentrate Agreement With MediPharm

Cronos announces that it has entered into a multi-year private label cannabis concentrate supply agreement MediPharm Labs.

Stocks Spring Back: Cramer's 'Mad Money' Recap (Friday 5/10/19)

Stocks Spring Back: Cramer's 'Mad Money' Recap (Friday 5/10/19)

The markets staged a big reversal Friday after the China tariffs and Uber's IPO thud. Jim Cramer's got your game plan for next week.

ADT, Domo, Aurora Cannabis: 'Mad Money' Lightning Round

ADT, Domo, Aurora Cannabis: 'Mad Money' Lightning Round

Jim Cramer takes a look at ADT, Domo, Aurora Cannabis, Seaspan, Walgreens Boots Alliance, Sirius XM Radio and more.

Cronos Falls Despite Swinging to Small First-Quarter Profit

Cronos Falls Despite Swinging to Small First-Quarter Profit

Cronos shares are falling despite easily topping analysts' earnings estimates.

Ask Cramer: Cannabis ETF vs. Individual Stock: Which to Buy?

Ask Cramer: Cannabis ETF vs. Individual Stock: Which to Buy?

Should you buy cannabis ETF instead of attempting to pick an individual stock?

Altria Shares Fall After Tobacco Maker Misses Earnings Estimates

Altria Shares Fall After Tobacco Maker Misses Earnings Estimates

The tobacco maker misses expectations in the first quarter on both the top and bottom lines. It reiterates 2019 earnings guidance.

Toke'n Economy: Pot Stock Investment Advice For 4/20 Weekend

Toke'n Economy: Pot Stock Investment Advice For 4/20 Weekend

Pot stocks may have cooled off in recent months but the industry is still hot and Bank of America Merrill Lynch expects it to get hotter as it reaches maturity.

Jim Cramer: It's 420, Here's How to Play the Cannabis Sector

Jim Cramer: It's 420, Here's How to Play the Cannabis Sector

It's 420. TheStreet's Jim Cramer discusses Canopy Growth, Tilray, Constellation Brands and other investing opportunities in the cannabis sector!

Canopy Growth Now Has to be Considered the Leader in the Canadian Cannabis Space

Canopy Growth Now Has to be Considered the Leader in the Canadian Cannabis Space

CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.

HEXO Is Top Pick as Bank of America Initiates Cannabis Coverage

HEXO Is Top Pick as Bank of America Initiates Cannabis Coverage

Bank of America doesn't see the cannabis market becoming mature in Canada until 2021.

Bankers on the Grill: Cramer's 'Mad Money' Recap (Wednesday 4/10/19)

Bankers on the Grill: Cramer's 'Mad Money' Recap (Wednesday 4/10/19)

Averages barely budge, despite grilling of banking CEOS by lawmakers. Jim Cramer talks about earnings and the great divide in Washington.

Yeti holdings, Tandem Diabetes, Electronic Arts: 'Mad Money' Lightning Round

Yeti holdings, Tandem Diabetes, Electronic Arts: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Yeti holdings, Tandem Diabetes Care, Electronic Arts, Aurora Cannabis, PacWest Bancorp and more.

Why CBD's Invasion Into Pantries and Medicine Cabinets Is Inevitable

Why CBD's Invasion Into Pantries and Medicine Cabinets Is Inevitable

Cannabis' non-psychoactive derivative could disrupt the CPG (Consumer Product Group) space very soon. Watch the video for the more on the opportunities and challenges.

Wall of Worry: Cramer's 'Mad Money' Recap (Wednesday 4/3/19)

Wall of Worry: Cramer's 'Mad Money' Recap (Wednesday 4/3/19)

Jim Cramer loves to see stories about worries at the start of earnings season. Lowered expectations are the best kind of expectations and they can make for great markets, he says.

Cronos Group's High Times May Be About to Wear Off

Cronos Group's High Times May Be About to Wear Off

Charts of this type are frequently found to be topping patterns.

Cronos Cracks After Canaccord Downgrade and Bearish Canadian Adult-Use Outlook

Cronos Cracks After Canaccord Downgrade and Bearish Canadian Adult-Use Outlook

Analysts at Canaccord downgrade the company's Canadian-traded stock to sell while maintaining a C$17 price target.

Revenue at Cronos Rises but Its Losses Widen in 2018

Revenue at Cronos Rises but Its Losses Widen in 2018

Cronos shares fall sharply after the cannabis company swings to a loss in the fiscal year.

Altria or Philip Morris International: Which Is the Better Dividend Stock?

Altria or Philip Morris International: Which Is the Better Dividend Stock?

While the two tobacco giants have similar yields, both also have very different businesses, with different growth potential in the years ahead.

Use Caution on Small-Caps, Plus Apple, Tesla and McDonald's: Market Recon

Use Caution on Small-Caps, Plus Apple, Tesla and McDonald's: Market Recon

Equity markets marked time on Monday, mostly on light volume.

Cronos Group Certainly Qualifies for Mainstream Consideration

Cronos Group Certainly Qualifies for Mainstream Consideration

Revenue is where it's at for cannabis in 2019.

2 Big Earnings Reports I'll Be Watching This Week

2 Big Earnings Reports I'll Be Watching This Week

A huge week is coming up for these well-known stocks.

Don't Be a Hero: Cramer's 'Mad Money' Recap (Friday 3/22/19)

Don't Be a Hero: Cramer's 'Mad Money' Recap (Friday 3/22/19)

Jim Cramer says there's so much money being run by computers, stocks are virtually destined to come down in this situation. Here's the game plan.

7 Indirect Stock Plays on the Cannabis Sector

7 Indirect Stock Plays on the Cannabis Sector

Investors can gain exposure to the high-flying cannabis industry without taking on undue risks.

What Metric Jim Cramer Watches in Every Cannabis Earnings Report

What Metric Jim Cramer Watches in Every Cannabis Earnings Report

Overwhelmed by the cannabis earnings reports? Here's the metric that Jim Cramer watches.

The Fed's March Meeting: 3 Things Stock Investors Should Look Out For

The Fed's March Meeting: 3 Things Stock Investors Should Look Out For

Plus, why investors should care about the yield curve, and a closer look at Tilray's quarter.

Pot Stocks Trade Mixed Following Tilray's Fourth-Quarter Results

Pot Stocks Trade Mixed Following Tilray's Fourth-Quarter Results

Tilray shares turn following the company's fourth-quarter results while other pot stocks trade mixed.

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.

TheStreet Quant Rating: C+ (Hold)